{"id":"ervebo-booster","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ervebo is a live attenuated VSV vector vaccine expressing the Ebola virus glycoprotein, which primes the immune system. The booster dose is administered to enhance and prolong protective immunity after an initial Ervebo vaccination series. This heterologous prime-boost strategy leverages the VSV platform to generate robust cellular and humoral immune responses against Ebola.","oneSentence":"Ervebo booster is a recombinant vesicular stomatitis virus (VSV)-based vaccine booster designed to enhance and sustain immune responses against Ebola virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:24.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ebola virus disease prevention (booster vaccination in previously primed individuals)"}]},"trialDetails":[{"nctId":"NCT05959421","phase":"PHASE3","title":"Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure","status":"NOT_YET_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2026-06","conditions":"Ebola Vaccine","enrollment":70},{"nctId":"NCT06126822","phase":"PHASE3","title":"Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2025-02-25","conditions":"Ebola Virus Disease","enrollment":624}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ervebo® booster","genericName":"Ervebo® booster","companyName":"Institute of Tropical Medicine, Belgium","companyId":"institute-of-tropical-medicine-belgium","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ervebo booster is a recombinant vesicular stomatitis virus (VSV)-based vaccine booster designed to enhance and sustain immune responses against Ebola virus. Used for Ebola virus disease prevention (booster vaccination in previously primed individuals).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}